Legend431, I do not compare NWBio to other biotech companies. I do not compare the DCVax vaccine platform to other new drugs or biologics. The DCVax vaccine platform will be a foundational / core part of the new standard of care (SOC) to treat ndGBM and rGBM patients worldwide. It is my hope, that the DCVax vaccine platform will become a breakthrough new treatment tool to treat all of most solid tumor cancers worldwide.
NWBio has been working closely with, and communicating and coordinating with regulatory authorities in the US, Canada, UK, Germany and the rest of the EU, with the primary view and goal of getting DCVax-L commercially approved to treat both ndGBM and rGBM patients.
NWBio developed a plan, after data-lock, that included a "Quiet Period" for the regulatory processes to play out, and their plans also included having the DCVax-L Phase III results published in a top tier peer-reviewed medical journal about the same time as the official top line data (TLD) results are officially PRed and released directly by NWBio. The selected journal publication also has an embargo policy, and NWBio is making sure that the Quiet Period also keeps them in compliance with these embargo policies.
I have confidence in NWBio's leadership and its senior management team, I don't feel a need to second guess them, or question their timing. I understand that they have been directly communicating with the regulators, and they have access to a lot more first-hand information than anyone on this board.
I have taken full advantage of the Quiet Period, by buying and accumulating more NWBO shares since data-lock (October 2020), and even more so since May 10, 2022, after it was disclosed that the DCVax-L Phase III trial was a success, and it met both its Primary and Secondary Endpoints with statistical significance.
AI
Market Data 
Markets 
